Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review

ConclusionsEvidence informing the use of BMA beyond 2  years is heterogeneous and based on retrospective analysis. Prospective randomized studies with greater emphasis on quality of life are needed.PROSPERO registration numberCRD42019126813
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research